-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $355

Benzinga·05/19/2026 14:31:45
Listen to the news
Citigroup analyst Eric Joseph initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $355.